## Kapil Mehta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10921715/publications.pdf

Version: 2024-02-01

		87723	161609
65	5,549	38	54
papers	citations	h-index	g-index
65	65	65	5944
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene, 2002, 21, 8843-8851.	2.6	383
2	Transglutaminase Regulation of Cell Function. Physiological Reviews, 2014, 94, 383-417.	13.1	353
3	Human CD38: a glycoprotein in search of a function. Trends in Immunology, 1994, 15, 95-97.	7.5	331
4	Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Molecular Cancer Therapeutics, 2007, 6, 1276-1282.	1.9	302
5	Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines. Anti-Cancer Drugs, 1997, 8, 470-481.	0.7	290
6	Human CD38, a cellâ€surface protein with multiple functions. FASEB Journal, 1996, 10, 1408-1417.	0.2	264
7	Human CD38: a (r)evolutionary story of enzymes and receptors. Leukemia Research, 2001, 25, 1-12.	0.4	258
8	Liposome-Encapsulated Curcumin Suppresses Growth of Head and Neck Squamous Cell Carcinoma <i>In vitro</i> and in Xenografts through the Inhibition of Nuclear Factor PB by an AKT-Independent Pathway. Clinical Cancer Research, 2008, 14, 6228-6236.	3.2	193
9	Overexpression of Tissue Transglutaminase Leads to Constitutive Activation of Nuclear Factor-l <sup>o</sup> B in Cancer Cells: Delineation of a Novel Pathway. Cancer Research, 2006, 66, 8788-8795.	0.4	188
10	Prognostic Significance of Tissue Transglutaminase in Drug Resistant and Metastatic Breast Cancer. Clinical Cancer Research, 2004, 10, 8068-8076.	3.2	187
11	Tissue transglutaminase: an enzyme with a split personality. International Journal of Biochemistry and Cell Biology, 1999, 31, 817-836.	1.2	171
12	Increased Expression of Tissue Transglutaminase in Pancreatic Ductal Adenocarcinoma and Its Implications in Drug Resistance and Metastasis. Cancer Research, 2006, 66, 10525-10533.	0.4	150
13	Tissue transglutaminase-induced alterations in extracellular matrix inhibit tumor invasion.  Molecular Cancer, 2005, 4, 33.	7.9	139
14	Antitumor Metallothiosemicarbazonates:Â Structure and Antitumor Activity of Palladium Complex of Phenanthrenequinone Thiosemicarbazone. Inorganic Chemistry, 2005, 44, 1154-1156.	1.9	129
15	Transglutaminase 2: A multi-tasking protein in the complex circuitry of inflammation and cancer. Biochemical Pharmacology, 2010, 80, 1921-1929.	2.0	129
16	Tissue Transglutaminase Inhibits Autophagy in Pancreatic Cancer Cells. Molecular Cancer Research, 2007, 5, 241-249.	1.5	123
17	Tissue Transglutaminase Promotes Drug Resistance and Invasion by Inducing Mesenchymal Transition in Mammary Epithelial Cells. PLoS ONE, 2010, 5, e13390.	1.1	110
18	High levels of transglutaminase expression in doxorubicin-resistant human breast carcinoma cells. International Journal of Cancer, 1994, 58, 400-406.	2.3	106

#	Article	IF	Citations
19	Implications of tissue transglutaminase expression in malignant melanoma. Molecular Cancer Therapeutics, 2006, 5, 1493-1503.	1.9	97
20	Therapeutic Significance of Elevated Tissue Transglutaminase Expression in Pancreatic Cancer. Clinical Cancer Research, 2008, 14, 2476-2483.	3.2	95
21	Clinical and Biological Significance of Tissue Transglutaminase in Ovarian Carcinoma. Cancer Research, 2008, 68, 5849-5858.	0.4	90
22	Tissue transglutaminase-mediated chemoresistance in cancer cells. Drug Resistance Updates, 2007, 10, 144-151.	6.5	88
23	Tissue Transglutaminase Regulates Focal Adhesion Kinase/AKT Activation by Modulating PTEN Expression in Pancreatic Cancer Cells. Clinical Cancer Research, 2008, 14, 1997-2005.	3.2	84
24	Tissue Transglutaminase Constitutively Activates HIF-1α Promoter and Nuclear Factor-κB via a Non-Canonical Pathway. PLoS ONE, 2012, 7, e49321.	1.1	84
25	Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer. Breast Cancer Research, 2013, 15, 202.	2.2	78
26	PKCδ and Tissue Transglutaminase are Novel Inhibitors of Autophagy in Pancreatic Cancer Cells. Autophagy, 2007, 3, 480-483.	4.3	76
27	Tissue transglutaminase: from biological glue to cell survival cues. Frontiers in Bioscience - Landmark, 2006, 11, 173.	3.0	70
28	Tissue transglutaminase promotes or suppresses tumors depending on cell context. Anticancer Research, 2009, 29, 1909-19.	0.5	63
29	Post-translational Modification of CD38 Protein into a High Molecular Weight Form Alters Its Catalytic Properties. Journal of Biological Chemistry, 1996, 271, 15922-15927.	1.6	60
30	Evidence That Aberrant Expression of Tissue Transglutaminase Promotes Stem Cell Characteristics in Mammary Epithelial Cells. PLoS ONE, 2011, 6, e20701.	1.1	56
31	Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells. Breast Cancer Research, 2012, 14, R4.	2.2	54
32	Involvement of Retinoic Acid Receptor-α–Mediated Signaling Pathway in Induction of CD38 Cell-Surface Antigen. Blood, 1997, 89, 3607-3614.	0.6	53
33	Multidrug-resistant MCF-7 breast cancer cells contain deficient intracellular calcium pools. Breast Cancer Research and Treatment, 2002, 71, 237-247.	1.1	51
34	Drug-resistant breast carcinoma (MCF-7) cells are paradoxically sensitive to apoptosis. Journal of Cellular Physiology, 2004, 200, 223-234.	2.0	50
35	Tissue Transglutaminase (TG2) in Cancer Biology. , 2005, 38, 125-138.		50
36	Transglutaminase 2 reprogramming of glucose metabolism in mammary epithelial cells via activation of inflammatory signaling pathways. International Journal of Cancer, 2014, 134, 2798-2807.	2.3	45

#	Article	IF	Citations
37	Mammalian Transglutaminases: A Family Portrait. , 2005, 38, 1-18.		44
38	Transglutaminase-2: evolution from pedestrian protein to a promising therapeutic target. Amino Acids, 2017, 49, 425-439.	1.2	41
39	Purification and characterization of a novel transglutaminase from filarial nematode Brugia malayi. FEBS Journal, 1994, 225, 625-634.	0.2	39
40	Tissue transglutaminase, inflammation, and cancer: how intimate is the relationship?. Amino Acids, 2013, 44, 81-88.	1.2	39
41	Targeting p70S6K Prevented Lung Metastasis in a Breast Cancer Xenograft Model. Molecular Cancer Therapeutics, 2010, 9, 1180-1187.	1.9	37
42	Transglutaminase-Mediated Activation of Nuclear Transcription Factor-& Transcription Factor-& In Cancer Cells: A New Therapeutic Opportunity. Current Cancer Drug Targets, 2007, 7, 559-565.	0.8	35
43	Multidrug-Resistant MCF-7 Cells: An Identity Crisis?. Journal of the National Cancer Institute, 2002, 94, 1652-b-1654.	3.0	33
44	Retinoic acid-induced CD38 antigen promotes leukemia cells attachment and interferon- $\hat{I}^3$ /interleukin- $\hat{I}^2$ -dependent apoptosis of endothelial cells: Implications in the etiology of retinoic acid syndrome. Leukemia Research, 2007, 31, 455-463.	0.4	30
45	Tissue transglutaminase induces the release of apoptosis inducing factor and results in apoptotic death of pancreatic cancer cells. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 1455-1463.	2.2	29
46	Tissue transglutaminase expression promotes castration-resistant phenotype and transcriptional repression of androgen receptor. European Journal of Cancer, 2014, 50, 1685-1696.	1.3	24
47	Significance of transglutaminase-catalyzed reactions in growth and development of filarial parasite, Brugia malayi. Biochemical and Biophysical Research Communications, 1990, 173, 1051-1057.	1.0	21
48	Induction of Tissue Transglutaminase in Human Peripheral Blood Monocytes by Intracellular Delivery of Retinoids. Journal of Leukocyte Biology, 1987, 41, 341-348.	1.5	19
49	Retinoid-Mediated Signaling Pathways in CD38 Antigen Expression in Myeloid Leukemia Cells. Leukemia and Lymphoma, 1999, 32, 441-449.	0.6	18
50	Human breast cancer MCF-7 cell line contains inherently drug-resistant subclones with distinct genotypic and phenotypic features. International Journal of Oncology, 2002, 20, 913.	1.4	18
51	Tissue Transglutaminase (TG2)-Induced Inflammation in Initiation, Progression, and Pathogenesis of Pancreatic Cancer. Cancers, 2011, 3, 897-912.	1.7	18
52	Induction of Adenosine Deaminase and 5′ Nucleotidase Activity in Cultured Human Blood Monocytes and Monocytic Leukemia (THP-1) Cells by Differentiating Agents. Journal of Leukocyte Biology, 1988, 44, 205-211.	1.5	16
53	N-linked glycosylation of CD38 is required for its structure stabilization but not for membrane localization. Molecular and Cellular Biochemistry, 2007, 295, 1-7.	1.4	14
54	Transglutaminase Levels and Immunologic Functions of BCG-Elicited Mouse Peritoneal Macrophages Isolated by Centrifugal Elutriation. Journal of Leukocyte Biology, 1989, 45, 434-443.	1.5	8

#	Article	IF	Citations
55	Targeting Transglutaminase-2 to Overcome Chemoresistance in Cancer Cells., 2009,, 95-114.		6
56	Retinoid-Mediated Signaling and CD38 Expression. , 2002, , 409-425.		3
57	Involvement of Retinoic Acid Receptor-α–Mediated Signaling Pathway in Induction of CD38 Cell-Surface Antigen. Blood, 1997, 89, 3607-3614.	0.6	3
58	Retinoic acid-a player that rules the game of life and death in neutrophils. Indian Journal of Experimental Biology, 2002, 40, 874-81.	0.5	2
59	Transglutaminases of Lower Organisms. , 2005, 38, 209-222.		1
60	Transglutaminase-2., 2014, , 1-3.		1
61	Tissue transglutaminase expression and drug resistance in ovarian cancer. Expert Review of Obstetrics and Gynecology, 2009, 4, 105-110.	0.4	O
62	Transglutaminase II and Metastasis: How Hot Is the Link?., 2015,, 215-228.		0
63	Transglutaminase-2. , 2011, , 3764-3766.		O
64	TG2: Player That Dictates the Rules in Cancer Progression. , 2015, , 129-136.		0
65	Transglutaminase-2. , 2017, , 4634-4637.		O